Development of Small-Molecule MERS-CoV Inhibitors

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2018 Dec 20

PMID 30562987

Citations 40

Authors

Ruiying Liang

Lili Wang

Naru Zhang

Xiaoqian Deng

Meng Su

Yudan Su

Lanfang Hu

Chen He

Tianlei Ying

Shibo Jiang

Fei Yu

Affiliations

Soon will be listed here.

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) with potential to cause global pandemics remains a threat to the public health, security, and economy. In this review, we focus on advances in the research and development of small-molecule MERS-CoV inhibitors targeting different stages of the MERS-CoV life cycle, aiming to prevent or treat MERS-CoV infection.

Citing Articles

Mucosal immunity in upper and lower respiratory tract to MERS-CoV.

Shrwani K, Mahallawi W, Mohana A, Algaissi A, Dhayhi N, Sharwani N Front Immunol. 2024; 15:1358885.

PMID: 39281686 PMC: 11392799. DOI: 10.3389/fimmu.2024.1358885.

Viral Factors in Modulation of Host Immune Response: A Route to Novel Antiviral Agents and New Therapeutic Approaches.

Tarasova O, Petrou A, Ivanov S, Geronikaki A, Poroikov V Int J Mol Sci. 2024; 25(17).

PMID: 39273355 PMC: 11395507. DOI: 10.3390/ijms25179408.

Sulfated Glycans Inhibit the Interaction of MERS-CoV Receptor Binding Domain with Heparin.

Yang J, Song Y, Jin W, Xia K, Burnett G, Qiao W Viruses. 2024; 16(2).

PMID: 38400013 PMC: 10892611. DOI: 10.3390/v16020237.

Identification of SARS-CoV-2 Main Protease Inhibitors Using Chemical Similarity Analysis Combined with Machine Learning.

Juarez-Mercado K, Gomez-Hernandez M, Salinas-Trujano J, Cordova-Bahena L, Espitia C, Perez-Tapia S Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399455 PMC: 10892746. DOI: 10.3390/ph17020240.

An approach to develop potential therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Biswas S, Mita M, Afrose S, Hasan M, Shimu M, Zaman S Heliyon. 2024; 10(4):e25837.

PMID: 38379969 PMC: 10877303. DOI: 10.1016/j.heliyon.2024.e25837.

References

Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L . Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014; 194:200-10. PMC: 7114414. DOI: 10.1016/j.virusres.2014.10.007. View

Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R . Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659. PMC: 4892125. DOI: 10.1016/j.cell.2009.06.034. View

Bertram S, Glowacka I, Blazejewska P, Soilleux E, Allen P, Danisch S . TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J Virol. 2010; 84(19):10016-25. PMC: 2937781. DOI: 10.1128/JVI.00239-10. View

Hsu M, Kuo C, Chang K, Chang H, Chou C, Ko T . Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem. 2005; 280(35):31257-66. PMC: 8062786. DOI: 10.1074/jbc.M502577200. View

Dyall J, Coleman C, Hart B, Venkataraman T, Holbrook M, Kindrachuk J . Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014; 58(8):4885-93. PMC: 4136000. DOI: 10.1128/AAC.03036-14. View

Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y . Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol. 2013; 87(24):13134-40. PMC: 3838252. DOI: 10.1128/JVI.02433-13. View

Li H, Kuok D, Cheung M, Ng M, Ng K, Hui K . Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model. Antiviral Res. 2018; 155:89-96. PMC: 7113667. DOI: 10.1016/j.antiviral.2018.05.007. View

McFadden G . Gleevec casts a pox on poxviruses. Nat Med. 2005; 11(7):711-2. DOI: 10.1038/nm0705-711. View

Hu T, Zhang Y, Li L, Wang K, Chen S, Chen J . Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. Virology. 2009; 388(2):324-34. PMC: 7103376. DOI: 10.1016/j.virol.2009.03.034. View

10.

Kumar V, Shin J, Shie J, Ku K, Kim C, Go Y . Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL inhibitors. Antiviral Res. 2017; 141:101-106. PMC: 7113684. DOI: 10.1016/j.antiviral.2017.02.007. View

11.

Liu Q, Xia S, Sun Z, Wang Q, Du L, Lu L . Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2014; 59(1):742-4. PMC: 4291393. DOI: 10.1128/AAC.03977-14. View

12.

Kim Y, Liu H, Galasiti Kankanamalage A, Weerasekara S, Hua D, Groutas W . Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016; 12(3):e1005531. PMC: 4814111. DOI: 10.1371/journal.ppat.1005531. View

13.

Cotten M, Watson S, Zumla A, Makhdoom H, Palser A, Ong S . Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. mBio. 2014; 5(1). PMC: 3944817. DOI: 10.1128/mBio.01062-13. View

14.

Lu L, Liu Q, Zhu Y, Chan K, Qin L, Li Y . Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014; 5:3067. PMC: 7091805. DOI: 10.1038/ncomms4067. View

15.

Ren Z, Yan L, Zhang N, Guo Y, Yang C, Lou Z . The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease. Protein Cell. 2013; 4(4):248-50. PMC: 4875521. DOI: 10.1007/s13238-013-2841-3. View

16.

Zhao G, Du L, Ma C, Li Y, Li L, Poon V . A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J. 2013; 10:266. PMC: 3765664. DOI: 10.1186/1743-422X-10-266. View

17.

Chou C, Lai H, Chen H, Cheng S, Cheng K, Chou Y . Structural basis for catalysis and ubiquitin recognition by the severe acute respiratory syndrome coronavirus papain-like protease. Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 2):572-81. PMC: 7161584. DOI: 10.1107/S1399004713031040. View

18.

Engel J, Doyle P, Hsieh I, McKerrow J . Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med. 1998; 188(4):725-34. PMC: 2213346. DOI: 10.1084/jem.188.4.725. View

19.

Wang C, Zhao L, Xia S, Zhang T, Cao R, Liang G . De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018; 61(19):8734-8745. PMC: 7075651. DOI: 10.1021/acs.jmedchem.8b00890. View

20.

Harcourt B, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson K, Smith C . Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol. 2004; 78(24):13600-12. PMC: 533933. DOI: 10.1128/JVI.78.24.13600-13612.2004. View